Wang R - Search Results

1

Correction to: ⁶⁸Ga-FAPI outperforms ¹⁸F-FDG PET/CT in identifying solitary fibrous tumor.

Wang R, Liu Q, Sui H, Zhang M, Zhu Z, Cui R. Wang R, et al. Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):2064-2065. doi: 10.1007/s00259-021-05228-z. Eur J Nucl Med Mol Imaging. 2021. PMID: 33656579 No abstract available.

2

¹⁷⁷Lu-EB-PSMA Radioligand Therapy with Escalating Doses in Patients with Metastatic Castration-Resistant Prostate Cancer.

Zang J, Liu Q, Sui H, Wang R, Jacobson O, Fan X, Zhu Z, Chen X. Zang J, et al. Among authors: wang r. J Nucl Med. 2020 Dec;61(12):1772-1778. doi: 10.2967/jnumed.120.242263. Epub 2020 May 1. J Nucl Med. 2020. PMID: 32358086 Free PMC article. Clinical Trial.

3

Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of ¹⁷⁷Lu-DOTA-EB-TATE.

Liu Q, Zang J, Sui H, Ren J, Guo H, Wang H, Wang R, Jacobson O, Zhang J, Cheng Y, Zhu Z, Chen X. Liu Q, et al. Among authors: wang h, wang r. J Nucl Med. 2021 Mar;62(3):386-392. doi: 10.2967/jnumed.120.248658. Epub 2020 Aug 21. J Nucl Med. 2021. PMID: 32826319 Free PMC article.

4

⁶⁸Ga-FAPI outperforms ¹⁸F-FDG PET/CT in identifying solitary fibrous tumor.

Wang R, Liu Q, Sui H, Zhang M, Zhu Z, Cui R. Wang R, et al. Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):2055-2056. doi: 10.1007/s00259-020-05181-3. Epub 2021 Jan 19. Eur J Nucl Med Mol Imaging. 2021. PMID: 33469685 No abstract available.

5

Portal Biliopathy and Cavernous Transformation of the Portal Vein Revealed by 68Ga-FAPI PET/CT.

Wang R, Gao X, Han X, Zhu Z, He X. Wang R, et al. Clin Nucl Med. 2022 Feb 1;47(2):161-163. doi: 10.1097/RLU.0000000000003815. Clin Nucl Med. 2022. PMID: 34269727

6

A prospective head-to-head comparison of ⁶⁸ Ga-NOTA-3P-TATE-RGD and ⁶⁸ Ga-DOTATATE in patients with gastroenteropancreatic neuroendocrine tumours.

Jiang Y, Liu Q, Wang G, Sui H, Wang R, Wang J, Zhu Z. Jiang Y, et al. Among authors: wang g, wang j, wang r. Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):4218-4227. doi: 10.1007/s00259-022-05852-3. Epub 2022 Jun 3. Eur J Nucl Med Mol Imaging. 2022. PMID: 35657429 Clinical Trial.

7

Safety and efficacy of peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors.

Jiang Y, Liu Q, Wang G, Sui H, Wang R, Wang J, Zhang J, Zhu Z, Chen X. Jiang Y, et al. Among authors: wang g, wang j, wang r. Theranostics. 2022 Sep 6;12(15):6437-6445. doi: 10.7150/thno.77219. eCollection 2022. Theranostics. 2022. PMID: 36185603 Free PMC article.

8

A Single-Arm, Low-Dose, Prospective Study of ¹⁷⁷Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.

Wang G, Zang J, Jiang Y, Liu Q, Sui H, Wang R, Fan X, Zhang J, Zhu Z, Chen X. Wang G, et al. Among authors: wang r. J Nucl Med. 2023 Apr;64(4):611-617. doi: 10.2967/jnumed.122.264857. Epub 2022 Nov 3. J Nucl Med. 2023. PMID: 36328486 Free article.

9

Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracer ^99mTc-HP-Ark2: a pilot study.

Shi J, Du S, Wang R, Gao H, Luo Q, Hou G, Zhou Y, Zhu Z, Wang F. Shi J, et al. Among authors: wang f, wang r. J Transl Med. 2023 Jan 11;21(1):19. doi: 10.1186/s12967-022-03865-y. J Transl Med. 2023. PMID: 36631812 Free PMC article.

10

The value of ¹⁸F-FDG PET/CT in the systemic evaluation of patients with Rosai-Dorfman disease: a retrospective study and literature review.

Lu X, Wang R, Zhu Z. Lu X, et al. Among authors: wang r. Orphanet J Rare Dis. 2023 May 13;18(1):116. doi: 10.1186/s13023-023-02711-8. Orphanet J Rare Dis. 2023. PMID: 37179326 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

42,290 results

Search Page

Filters